OPKO Health Takes 15% Stake in Nicoya as RAYALDEE Expansion Accelerates
Event summary
- OPKO Health's subsidiary EirGen Pharma acquired a 15% equity stake in Nicoya Therapeutics under an amended agreement.
- The deal reinforces Nicoya’s commitment to commercialize RAYALDEE® in Greater China, with regulatory approvals expected in 2027.
- OPKO stands to receive up to $115 million in milestones from the collaboration.
- RAYALDEE is already approved in Macau for treating secondary hyperparathyroidism (SHPT) in chronic kidney disease patients.
The big picture
OPKO Health is deepening its footprint in the Greater China nephrology market through this expanded partnership with Nicoya. The deal underscores the strategic importance of RAYALDEE, which addresses a significant unmet need among chronic kidney disease patients. With over 20 million adults affected by stage 3 or 4 CKD in China, the commercial potential is substantial if regulatory and execution hurdles are cleared.
What we're watching
- Regulatory Timing
- Whether Nicoya can secure regulatory approvals for RAYALDEE in China and related territories by 2027.
- Market Penetration
- The pace at which RAYALDEE gains adoption in Greater China’s chronic kidney disease market.
- Strategic Alignment
- How OPKO’s equity stake in Nicoya influences its broader Asia strategy and potential future collaborations.